Purushothaman Jayamurthy
Purushothaman Jayamurthy has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Eveline M. Anto
Department of Biochemistry, Agro-Processing & Technology Division, CSIR-National Institute for Interdisciplinary Science & Technology, Thiruvananthapuram, India
3 shared publicationsP. Nisha
Agro-Processing and Technology Division, CSIR-NIIST, Thiruvananthapuram 695 019, Kerala, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
3 shared publicationsA. D. Arya
Process Engineering and Environmental Technology, National Institute for Interdisciplinary Science and Technology, Council of Scientific and Industrial ResearchPappanamcode, India
2 shared publicationsAnaga Nair
CSIR-National Institute for Interdisciplinary Science and Technology
2 shared publicationsEveline M Anto
Department of Biochemistry, Agro & Food Processing Technology Division, CSIR-National Institute for Interdisciplinary Science & Technology, Thiruvananthapuram, Kerala, 695019, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
2 shared publicationsNair Anaga
Department of Biochemistry, Agro-Processing and Technology Division, CSIR–National Institute for Interdisciplinary Science and Technology, Thiruvananthapuram, India
2 shared publications
Latest Publications
- 15 April 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 818, 153773
ER stress: A putative therapeutic target for diabetes mellitus
- 15 April 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 818, 153773
ER stress: A putative therapeutic target for diabetes mellitus
- 23 March 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
(+)-Catechin mitigates impairment in insulin secretion and beta cell damage in methylglyoxal-induced pancreatic beta cells
Background The formation of advanced glycation end products (AGEs) is the central process contributing to diabetic complications in diabetic individuals with sustained and inconsistent hyperglycemia. Methylglyoxal, a reactive carbonyl species, is found to be a major precursor of AGEs, and its levels are elevated in diabetic conditions. Dysfunction of pancreatic beta cells and impairment in insulin secretion are the hallmarks of diabetic progression. Exposure to methylglyoxal-induced AGEs alters the function and maintenance of pancreatic beta cells. Hence, trapping methylglyoxal could be an ideal approach to alleviate AGE formation and its influence on beta cell proliferation and insulin secretion, thereby curbing the progression of diabetes to its complications. Methods and results In the present study, we have explored the mechanism of action of (+)-Catechin against methylglyoxal-induced disruption in pancreatic beta cells via molecular biology techniques, mainly western blot. Methylglyoxal treatment decreased insulin synthesis (41.5%) via downregulating the glucose-stimulated insulin secretion pathway (GSIS). This was restored upon co-treatment with (+)-Catechin (29.9%) in methylglyoxal-induced Beta-TC-6 cells. Also, methylglyoxal treatment affected the autocrine function of insulin by disrupting the IRS1/PI3k/Akt pathway. Methylglyoxal treatment suppresses Pdx-1 and Maf A levels, which are responsible for beta cell maintenance and cell proliferation. (+)-Catechin could significantly augment the levels of these transcription factors. Conclusion This is the first study to examine the impact of a natural compound on methylglyoxal with the insulin-mediated autocrine and paracrine activities of pancreatic beta cells. The results indicate that (+)-Catechin exerts a protective effect against methylglyoxal exposure in pancreatic beta cells and can be considered a potential anti-glycation agent in further investigations on ameliorating diabetic complications.
- 23 March 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
(+)-Catechin mitigates impairment in insulin secretion and beta cell damage in methylglyoxal-induced pancreatic beta cells
Background The formation of advanced glycation end products (AGEs) is the central process contributing to diabetic complications in diabetic individuals with sustained and inconsistent hyperglycemia. Methylglyoxal, a reactive carbonyl species, is found to be a major precursor of AGEs, and its levels are elevated in diabetic conditions. Dysfunction of pancreatic beta cells and impairment in insulin secretion are the hallmarks of diabetic progression. Exposure to methylglyoxal-induced AGEs alters the function and maintenance of pancreatic beta cells. Hence, trapping methylglyoxal could be an ideal approach to alleviate AGE formation and its influence on beta cell proliferation and insulin secretion, thereby curbing the progression of diabetes to its complications. Methods and results In the present study, we have explored the mechanism of action of (+)-Catechin against methylglyoxal-induced disruption in pancreatic beta cells via molecular biology techniques, mainly western blot. Methylglyoxal treatment decreased insulin synthesis (41.5%) via downregulating the glucose-stimulated insulin secretion pathway (GSIS). This was restored upon co-treatment with (+)-Catechin (29.9%) in methylglyoxal-induced Beta-TC-6 cells. Also, methylglyoxal treatment affected the autocrine function of insulin by disrupting the IRS1/PI3k/Akt pathway. Methylglyoxal treatment suppresses Pdx-1 and Maf A levels, which are responsible for beta cell maintenance and cell proliferation. (+)-Catechin could significantly augment the levels of these transcription factors. Conclusion This is the first study to examine the impact of a natural compound on methylglyoxal with the insulin-mediated autocrine and paracrine activities of pancreatic beta cells. The results indicate that (+)-Catechin exerts a protective effect against methylglyoxal exposure in pancreatic beta cells and can be considered a potential anti-glycation agent in further investigations on ameliorating diabetic complications.
- 29 December 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Tangeretin enhances pancreatic beta-TC-6 function by ameliorating tunicamycin-induced cellular perturbations
Background Pancreatic beta cell health and its insulin-secreting potential are severely compromised under the diabetic condition. One of the key mediators of beta cell dysfunction is endoplasmic reticulum (ER) stress. Pharmacological intervention of ER stress and associated complications in pancreatic beta cells may be an effective strategy for the management of diabetes. In the present study, we evaluated the efficacy of tangeretin, a citrus pentamethoxyflavone, in the alleviation of ER stress and associated perturbations in pancreatic Beta-TC-6 cell lines. Methods and results Tunicamycin (pharmacological ER stress inducer) at subtoxic levels was observed to induce beta cell dysfunction by upregulation of intracellular ROS levels, lowering mitochondrial number/biogenesis and membrane potential, elevation of UPR markers, XBP-1, GADD153, and ER resident chaperones. Treatment with tangeretin was successful in improving the beta cell function by lowering the ROS levels and improving the mitochondrial biogenesis and mitochondrial membrane potential. Tangeretin also downregulated the expression levels of XBP-1, GADD153, and ER resident chaperones. GLUT2 expression, however, did not undergo any significant change under ER stress. We also observed altered expression of Pdx-1, TRB3, and p-Akt under the ER stress condition. Tangeretin augmented the expression levels of Pdx-1, and p-Akt while curtailing the expression of TRB3 in beta cells. Tunicamycin treatment suppressed the insulin levels, however, co-treatment with tangeretin could only marginally improve the levels. Conclusion Targeting ER stress and associated pathways in pancreatic Beta-TC-6 cell lines by tangeretin can be an effective strategy for improving beta cell function.
- 29 December 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Tangeretin enhances pancreatic beta-TC-6 function by ameliorating tunicamycin-induced cellular perturbations
Background Pancreatic beta cell health and its insulin-secreting potential are severely compromised under the diabetic condition. One of the key mediators of beta cell dysfunction is endoplasmic reticulum (ER) stress. Pharmacological intervention of ER stress and associated complications in pancreatic beta cells may be an effective strategy for the management of diabetes. In the present study, we evaluated the efficacy of tangeretin, a citrus pentamethoxyflavone, in the alleviation of ER stress and associated perturbations in pancreatic Beta-TC-6 cell lines. Methods and results Tunicamycin (pharmacological ER stress inducer) at subtoxic levels was observed to induce beta cell dysfunction by upregulation of intracellular ROS levels, lowering mitochondrial number/biogenesis and membrane potential, elevation of UPR markers, XBP-1, GADD153, and ER resident chaperones. Treatment with tangeretin was successful in improving the beta cell function by lowering the ROS levels and improving the mitochondrial biogenesis and mitochondrial membrane potential. Tangeretin also downregulated the expression levels of XBP-1, GADD153, and ER resident chaperones. GLUT2 expression, however, did not undergo any significant change under ER stress. We also observed altered expression of Pdx-1, TRB3, and p-Akt under the ER stress condition. Tangeretin augmented the expression levels of Pdx-1, and p-Akt while curtailing the expression of TRB3 in beta cells. Tunicamycin treatment suppressed the insulin levels, however, co-treatment with tangeretin could only marginally improve the levels. Conclusion Targeting ER stress and associated pathways in pancreatic Beta-TC-6 cell lines by tangeretin can be an effective strategy for improving beta cell function.
- Open Access
- 18 January 2023
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 28 (2) , 151-165
Tangeretin alleviates Tunicamycin-induced endoplasmic reticulum stress and associated complications in skeletal muscle cells
- 18 January 2023
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 28 (2) , 151-165
Open AccessTangeretin alleviates Tunicamycin-induced endoplasmic reticulum stress and associated complications in skeletal muscle cells
- 11 June 2021
- Published by Springer Nature
- p. 257-270
Emerging Role of Circulating Tumour DNA in Treatment Response Prognosis in Colon Cancer
- 11 June 2021
- Published by Springer Nature
- p. 257-270
Emerging Role of Circulating Tumour DNA in Treatment Response Prognosis in Colon Cancer
- 5 June 2021
- Published by Springer Nature
- p. 421-434
Probiotics in Colon Cancer: A Therapeutic Approach
- 1 December 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 105, 104375
Advanced glycation end-products (AGE) trapping agents: Design and synthesis of nature inspired indeno[2,1-c]pyridinones
- 1 December 2020
- Published by Elsevier in Bioorganic Chemistry
- Vol. 105, 104375
Advanced glycation end-products (AGE) trapping agents: Design and synthesis of nature inspired indeno[2,1-c]pyridinones
- 11 January 2020
- Published by Wiley in Cell Biochemistry and Function
- Vol. 38 (4) , 419-427
In vitro evaluation of antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stress in skeletal muscle cell line
The present study investigates the in vitro antidiabetic and antioxidant potential of hesperidin and hesperetin under oxidative stress induced in L6 myotubes. Also, the study attempts to reveal the effect of glycosylation (hesperetin) on the biological activities of hesperidin. Oxidative stress is the leading cause of complications associated with diabetes. Both hesperidin and hesperetin reduce oxidative stress directly by scavenging intracellular reactive oxygen species (ROS) and by up‐regulating natural antioxidant defence system like glutathione. Hesperidin and hesperetin at 10μM inhibited the non‐enzymatic glycation of proteins (65.57% and 35.6%, respectively), the critical reaction involved in the formation of advanced glycation end products (AGEs) which has a significant role in the pathogenesis of diabetes. Additionally, these compounds induced glucose uptake in L6 myotubes following acute and chronic treatment. The percentage 2‐NBDG uptake shown by both the compounds was comparable with that of the antidiabetic drug, rosiglitazone (30.4%). Both the compounds downregulated PI3 kinase activity whereas GLUT4, IRS, and AKT were upregulated in L6 myotubes pointing to the possible overlapping with the insulin signalling pathway.Significance of the study: Evidence suggest that oxidative stress occurs in diabetes and could have a role in the development of insulin resistance. Oral hypoglycaemic agents which target on increasing insulin levels and improving insulin sensitivity or that reduce the rate of carbohydrate absorption from the gastrointestinal tract are used to manage type 2 diabetes. But these therapies rarely target the real cause of type 2 diabetes and have severe adverse effects. The observations from the present study provide significant evidence for hesperidin and hesperetin, to be considered as a dietary supplement to manage type 2 diabetes and to suppress oxidative stress mediated diabetic pathophysiology.
- 11 January 2020
- Published by Wiley in Cell Biochemistry and Function
- Vol. 38 (4) , 419-427
In vitro evaluation of antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stress in skeletal muscle cell line
The present study investigates the in vitro antidiabetic and antioxidant potential of hesperidin and hesperetin under oxidative stress induced in L6 myotubes. Also, the study attempts to reveal the effect of glycosylation (hesperetin) on the biological activities of hesperidin. Oxidative stress is the leading cause of complications associated with diabetes. Both hesperidin and hesperetin reduce oxidative stress directly by scavenging intracellular reactive oxygen species (ROS) and by up‐regulating natural antioxidant defence system like glutathione. Hesperidin and hesperetin at 10μM inhibited the non‐enzymatic glycation of proteins (65.57% and 35.6%, respectively), the critical reaction involved in the formation of advanced glycation end products (AGEs) which has a significant role in the pathogenesis of diabetes. Additionally, these compounds induced glucose uptake in L6 myotubes following acute and chronic treatment. The percentage 2‐NBDG uptake shown by both the compounds was comparable with that of the antidiabetic drug, rosiglitazone (30.4%). Both the compounds downregulated PI3 kinase activity whereas GLUT4, IRS, and AKT were upregulated in L6 myotubes pointing to the possible overlapping with the insulin signalling pathway.Significance of the study: Evidence suggest that oxidative stress occurs in diabetes and could have a role in the development of insulin resistance. Oral hypoglycaemic agents which target on increasing insulin levels and improving insulin sensitivity or that reduce the rate of carbohydrate absorption from the gastrointestinal tract are used to manage type 2 diabetes. But these therapies rarely target the real cause of type 2 diabetes and have severe adverse effects. The observations from the present study provide significant evidence for hesperidin and hesperetin, to be considered as a dietary supplement to manage type 2 diabetes and to suppress oxidative stress mediated diabetic pathophysiology.
- 1 May 2018
- Published by Elsevier in Journal of Functional Foods
- Vol. 44, 218-226
Syzygium cumini seed attenuates LPS induced inflammatory response in murine macrophage cell line RAW264.7 through NF-κB translocation
- 1 May 2018
- Published by Elsevier in Journal of Functional Foods
- Vol. 44, 218-226
Syzygium cumini seed attenuates LPS induced inflammatory response in murine macrophage cell line RAW264.7 through NF-κB translocation
- Open Access
- 8 June 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 336
Quercetin, a Lead Compound against Type 2 Diabetes Ameliorates Glucose Uptake via AMPK Pathway in Skeletal Muscle Cell Line
Herein we investigated the molecular mechanism of action of the citrus flavonoid, quercetin in skeletal muscle cells (L6 myotubes). Taking advantage of protein kinase inhibitors, we proved that the effect of quercetin on 2-NBDG uptake in L6 myotubes was not through insulin signaling pathway, but through adenosine monophosphate kinase (AMPK) pathway and its downstream target p38 MAPK. An increase in the cellular AMP to ATP ratio on pretreatment may account for AMPK activation which was coupled with a transient change in mitochondrial membrane potential. In addition, quercetin triggered a rise in intracellular calcium suggesting that calcium-calmodulin mediated protein kinase (CaMKK) may also be involved. Quercetin shared a similar mechanism with the well-known drug metformin, highlighting it as a promising compound for the management of type 2 diabetes. The AMPK signaling pathway could contribute to correction of insulin resistance through bypassing the insulin-regulated system for GLUT4 translocation.
- 8 June 2017
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 336
Open AccessQuercetin, a Lead Compound against Type 2 Diabetes Ameliorates Glucose Uptake via AMPK Pathway in Skeletal Muscle Cell Line
Herein we investigated the molecular mechanism of action of the citrus flavonoid, quercetin in skeletal muscle cells (L6 myotubes). Taking advantage of protein kinase inhibitors, we proved that the effect of quercetin on 2-NBDG uptake in L6 myotubes was not through insulin signaling pathway, but through adenosine monophosphate kinase (AMPK) pathway and its downstream target p38 MAPK. An increase in the cellular AMP to ATP ratio on pretreatment may account for AMPK activation which was coupled with a transient change in mitochondrial membrane potential. In addition, quercetin triggered a rise in intracellular calcium suggesting that calcium-calmodulin mediated protein kinase (CaMKK) may also be involved. Quercetin shared a similar mechanism with the well-known drug metformin, highlighting it as a promising compound for the management of type 2 diabetes. The AMPK signaling pathway could contribute to correction of insulin resistance through bypassing the insulin-regulated system for GLUT4 translocation.